Liposome-Encapsulated Hemoglobin Ameliorates Impairment of Fear Memory and Hippocampal Dysfunction After Cerebral Ischemia in Rats

DOI Web Site PubMed 7 Citations 117 References
  • Hamadate Naobumi
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yamaguchi Taku
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Sugawara Aya
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Togashi Hiroko
    Department of Pharmacology, Faculty of Pharmaceutical Science, Health Science University of Hokkaido, Japan
  • Izumi Takeshi
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yoshida Takayuki
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Ohmura Yu
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yoshioka Mitsuhiro
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan

Bibliographic Information

Other Title
  • Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hypocampal dysfunction after cerebral ischemia in rats

Search this article

Abstract

Liposome-encapsulated hemoglobin (LEH) has been developed as a blood substitute. In spite of its size (1/30 – 1/40 of erythrocytes), LEH has an oxygen-carrying capacity comparable to erythrocytes. Thus, LEH is expected to carry oxygen into vital organs via collateral routes during ischemia induced by vascular embolism. In the present study, we examined the therapeutic effects of LEH on behavioral impairments in rats after four-vessel occlusion (4VO) for 30 min. In the open-field test, locomotor activity in 4VO rats did not alter 7 days after ischemia. However, in the contextual fear conditioning (CFC) test, the freezing rate was significantly decreased in 4VO rats, although no behavioral changes in the Y-maze test and elevated plus-maze test were observed. Phosphorylation of the cyclic AMP response element-binding protein (CREB) in the hippocampal CA1 region after the CFC test was attenuated. These 4VO-induced impairments were significantly alleviated by the administration of LEH (5 ml/kg, i.v.) during occlusion. Moreover, LEH did not alter hippocampal blood flow and tissue oxygen pressure during 4VO, but it did suppress hyperoxia after ischemia–reperfusion. These findings suggest that LEH, an artificial oxygen carrier, could be a novel therapeutic agent for brain dysfunction after acute cerebral ischemia.

Journal

Citations (7)*help

See more

References(117)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top